172 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
, competitive, industry, and market risks. The Company Board took into account these considerations in making its assessment that none of these alternatives … management of ImmunoGen regarding their assessment of the past and current business operations, financial condition and future prospects of ImmunoGen
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
, competitive, industry, and market risks. The Company Board took into account these considerations in making its assessment that none of these alternatives … management of ImmunoGen regarding their assessment of the past and current business operations, financial condition and future prospects of ImmunoGen
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
applicable Law or (B) any fine, assessment or cease and desist order, or the suspension, revocation or material restriction of any material Company … of limitations for the assessment or collection of any Tax of the Company or any of its Subsidiaries that is currently in force.
(e) Except as would
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
applicable Law or (B) any fine, assessment or cease and desist order, or the suspension, revocation or material restriction of any material Company … of limitations for the assessment or collection of any Tax of the Company or any of its Subsidiaries that is currently in force.
(e) Except as would
8-K
EX-99.1
dv9cpo8s ni80kfbn0
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
z78i3 1olcu
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
mvyg xc5z690ai
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
6amkmkqu qjm7pfugs
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
wgnje
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-10.1
wre2z7 4fow1
2 May 23
Entry into a Material Definitive Agreement
5:01pm